Media ReleasesBARD1 Life Sciences

View All BARD1 Life Sciences News

BARD1 Life Sciences Share Purchase Plan Completed Oversubscribed

• SPP successfully completed with oversubscribed applications of $3.4m accepted
• Total capital raised of $18.4m under both the SPP and recent placement to institutional and sophisticated investors
• BARD1 is now well funded with a pro forma cash balance of approximately $22.0m to advance its diagnostic programs towards key development and commercialisation milestones over the next 2 years

Melbourne, Australia, 23 August 2021: BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company) is pleased to announce that it has successfully completed the Share Purchase Plan (SPP) announced on 23 July 2021, with applications accepted for $3.4 million, including oversubscriptions. The Company was seeking to raise up to $2.0 million through the SPP. However, given the strong support for the SPP by eligible shareholders, the BARD1 Board has exercised its discretion to accept $3.4 million.

The SPP provided eligible shareholders with the opportunity to purchase new ordinary shares on the same terms as the recently completed placement to institutional and sophisticated investors (Placement) at $1.55 per share. The Placement was completed on Thursday, 29 July 2021 with a total of $15 million raised and 9,677,420 fully paid ordinary shares (Shares) issued that commenced trading on the ASX on 30 July 2021.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.